liver-2018-posters-accepted-abstracts

7 / 20

Page 45
Notes:
alliedacademies
Journal of Gastroenterology and Digestive Diseases | Volume 3
May 25-26, 2018 | New York, USA
World Liver Conference 2018
Background: The rates of obesityand themetabolic syndrome
are increasing worldwide, therefore clinical studies have
been undertaken to examine for links with Nonalcoholic fatty
liver disease (NAFLD), nonalcoholic steatohepatitis (NASH)
and hepatocellular carcinoma (HCC) NAFLD represents
the hepatic manifestation of the metabolic syndrome. It is
associated with the presence of insulin resistance and type
2 diabetes mellitus. HCC has been registered as a most
frequent type of cancer in type 2 diabetes.
Methods: Age, obesity, insulin resistance, and overall
development of metabolic syndrome are the major risk
factors associated with development of NAFLD. From
longitudinal studies performed in the Western countries, it
has been shown that rates of HCC from NASH are similar to
those of HCC from infection with the hepatitis C virus. Liver
biopsy is an invasive procedure and is not a suitable option
as a routine screening tool for this common disease and a
new diagnostic procedures and scoring systems that could
non-invasively distinguish simple steatosis from NASH are
emerging.
Results: Visceral body fat is related to the degree of
inflammation and fibrosis in NASH. The pro-inflammatory
environment can impact the liver and other tissues and
patients with more visceral fat had higher rates of HCC
recurrence. Part of patients who are initially diagnosed
as clinically non-cirrhotic NAFLD could be at high risk of
HCC development, and employing only standard follow-
up procedures for cirrhotic patients would not be enough.
Although current guidelines recommend regular HCC
surveillance for cirrhotic patients, HCC can develop in the
absence of cirrhosis in NAFLD.
Discussion: With the increasing prevalence of NAFLD it is
becoming clear that it will contribute to increasing incidence
of HCC as well. Identifying a high-risk subpopulation in
HCC development among non-cirrhotic NAFLD patients
is imperative. Obesity almost doubles the risk of HCC.
The diagnosis of HCC might be considered in obese and/
or diabetic patients with liver nodules, even if they do not
have others manifestations of chronic liver disease. Research
reported in this press release presentation was supported
by the Ostrava University, The Czech Republic, under grant
award number SGS03/LF/2018.
Speaker Biography
Toman D has completed his MD in 2012 from the University of Pavol Jozef Šafárik,
Faculty of Medicine, Košice, Slovakia. He is in his finalyear of residency program of
General Surgery. He has Pre-graduation experience from different European countries
(internships in Spain and Italy) and Post-graduation experience with internship in the
USA (Ryder Trauma Center, University of Miami, Miami, Florida, USA 6/2014) and has
given presentations at International Liver Conferences (7th APPLE conference in Hong
Kong 2016, The Liver Week 2017 in Seoul – The travel award winner). Since 2016, he is
a student of PhD at the Faculty of Medicine, Ostrava University in Ostrava, The Czech
Republic, and he focus on the study of NAFLD and HCC in patients with obesity and/
or metabolic syndrome.
e:
Non-alcoholic fatty liver disease and its development to hepatocellular carcinoma in patients with
obesity and metabolic syndrome
Toman D1, 2, Vávra P1, 2, 3, Ostruszka P1, 2, Jelínek P 1, 2, Peteja M1, 2 and Zonca P2
1Ostrava University, The Czech Republic
2University Hospital Ostrava, The Czech Republic
3VSB-Technical University of Ostrava, The Czech Republic